OspA-Based 6 valent Lyme vaccine shows >70% efficacy in phase 3 VALOR trial across individuals aged 5 years and older

Pfizer and Valneva announced topline Phase 3 VALOR data for their investigational 6‑valent OspA-based Lyme disease vaccine candidate PF‑07307405 (LB6V), reporting more than 70% efficacy in preventing Lyme disease in individuals aged 5 years and older and no safety concerns identified at the time of analysis. The vaccine is a multivalent protein subunit targeting outer surface protein A (OspA) of Borrelia burgdorferi sensu lato and induces antibodies against six OspA serotypes covering the most prevalent strains in North America and Europe; these antibodies act within the feeding tick to prevent transmission to the human host. PF‑07307405 is currently the most advanced Lyme vaccine candidate in clinical development, with two pivotal Phase 3 trials completed and an existing collaboration and license agreement under which Pfizer will exclusively manufacture and commercialize the vaccine, subject to regulatory approval. We reviewed Lyme borreliosis elsewhere in this issue of ViVa. VALOR was a multicenter, randomized, placebo-controlled,...